Picture loading failed.

Anti-NCAM1 therapeutic antibody (Pre-made Lorvotuzumab biosimilar,Whole mAb ADC) is a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for biological drug disovery items including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research.

Lorvotuzumab mertansine is designed for the treatment of CD56 positive cancers (e.g. small-cell lung cancer, ovarian cancer). It has been granted orphan drug status for Merkel cell carcinoma and has reported encouraging Phase II results for small-cell lung cancer (SCLC).

Order information

Delivery impact due to the Coronavirus Outbreak

With the COVID-19 outbreak in the world, many flights have been cancelled. In order for the customer to receive the goods properly, we use the FedEx Customized Freight (FCF) of Fedex which demands a higher fee. If the delivery fee is more expensive in your area, we will contact you by mail.

Catalog No. Package Price(In USD) Qty (Quantity) Sum(In USD)
GMP-Bios-ab-323-1mg 1mg Inquiry
GMP-Bios-ab-323-10mg 10mg Inquiry
GMP-Bios-ab-323-100mg 100mg Inquiry
GMP-Bios-ab-323-xmg ≥100mg Inquiry
Shipping Cost: 760.00


Products Name (INN Index) Anti-NCAM1 therapeutic antibody (Pre-made Lorvotuzumab biosimilar,Whole mAb ADC)
INN Name Lorvotuzumab
FormatWhole mAb ADC
Species ReactivityHuman
CH1 IsotypeIgG1
VD LCKappa
Highest_Clin_Trial (Jan '20)Phase-II
Est. StatusDiscontinued
100% SI StructureNone
99% SI StructureNone
95-98% SI StructureNone
Year Proposed2010
Year Recommended2011
Conditions Approvedna
Conditions Activena
Conditions DiscontinuedMultiple myeloma;Solid tumours;Small cell lung cancer
Development Techna